drugset / Trial / NCT01498952
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
Timeline
- Start
- 2012-01-17
- Primary completion
- 2013-04-09
- Completion
- 2013-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DUSIGITUMAB | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | DUSIGITUMAB | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | DUSIGITUMAB | Monoclonal antibody | 45 mg/kg | Intravenous |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |